Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
BRAF+
How would you treat a patient with BRAF V600E-mutated metastatic lung adenocarcinoma who has progressed on chemotherapy, immunotherapy and Dabrafenib/Trametinib?
Related Questions
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
How would you treat patient with a stage IV lung adenocarcinoma, an exon 21 p.H835L mutation, high TMB, and negative PD-L1?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
Would you consider the combination of amivantamab and lazertinib in a patient with NSCLC harboring an EGFR exon 19 deletion that transformed to small cell carcinoma on osimertinib, if resistance profiling still detects the EGFR mutation?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
Would you consider adding encorafenib + cetuximab to adjuvant mFOLFOX for a patient with oligometastatic colon cancer with BRAF V600E mutation s/p metastasectomy and primary resection given the new data from the BREAKWATER trial?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
In patients with stage III NSCLC who experience locoregional recurrence after neoadjuvant chemoimmunotherapy, surgery, and maintenance immunotherapy, and are treated with definitive chemoradiation at recurrence—what is the optimal systemic therapy strategy post-chemoradiation?
